In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy
- 31 August 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 69 (9), 1751-1766
- https://doi.org/10.1007/s00262-020-02575-y
Abstract
Primary central nervous system lymphoma (PCNSL) is a rare type of non-Hodgkin lymphoma with an aggressive clinical course. To investigate the potential of immune-checkpoint therapy, we retrospectively studied the tumor microenvironment (TME) using high-plex immunohistochemistry in 22 PCNSL and compared to 7 secondary CNS lymphomas (SCNSL) and 7 "other" CNSL lymphomas with the presence of the Epstein-Barr virus and/or compromised immunity. The TME in PCNSL was predominantly composed of CD8+ cytotoxic T cells and CD163+ phagocytes. Despite molecular differences between PCNSL and SCNSL, the cellular composition and the functional spectrum of cytotoxic T cells were similar. But cytotoxic T cell activation was significantly influenced by pre-biopsy corticosteroids intake, tumor expression of PD-L1 and the presence of EBV. The presence of low numbers of CD8+ T cells and geographic-type necrosis each predicted inferior outcome in PCNSL. Both M1-like (CD68 + CD163(low)) and M2-like (CD68 + CD163(high)) phagocytes were identified, and an increased ratio of M1-like/M2-like phagocytes was associated with a better survival. PD-L1 was expressed in lymphoma cells in 28% of cases, while PD1 was expressed in only 0.4% of all CD8+ T cells. TIM-3, a marker for T cell exhaustion, was significantly more expressed in CD8(pos)PD-1(pos) T cells compared to CD8(pos)PD-1(neg) T cells, and a similar increased expression was observed in M2-like pro-tumoral phagocytes. In conclusion, the clinical impact of TME composition supports the use of immune-checkpoint therapies in PCNSL. Based on observed differences in immune-checkpoint expression, combinations that boost cytotoxic T cell activation (by blocking TIM-3 or TGFBR1) prior to the administration of PD-L1 inhibition could be of interest.Funding Information
- KU Leuven (3M040406, OT14/101)
- Universitaire Ziekenhuizen Leuven, KU Leuven (RT0817)
This publication has 44 references indexed in Scilit:
- Other immunomodulatory agent-related lymphoproliferative diseases: a single-center series of 72 biopsy-confirmed casesLaboratory Investigation, 2018
- PD1 and PDL1 expression in primary central nervous system diffuse large B‐cell lymphoma are frequent and expression of PD1 predicts poor survivalHematological Oncology, 2016
- Role of the tumor microenvironment in mature B-cell lymphoid malignanciesHaematologica, 2016
- Primary central nervous system diffuse large B‐cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpartHistopathology, 2015
- The tumour microenvironment in B cell lymphomasNature Reviews Cancer, 2014
- Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphomaNeuro-Oncology, 2013
- M2 Macrophage/Microglial Cells Induce Activation of Stat3 in Primary Central Nervous System LymphomaJournal of Clinical and Experimental Hematopathology, 2011
- Primary lymphoma of the central nervous system: just DLBCL or not?Blood, 2009
- Primary central nervous system lymphomaJournal of Postgraduate Medicine, 2009
- Reactive perivascular T‐cell infiltrate predicts survival in primary central nervous system B‐cell lymphomasBritish Journal of Haematology, 2007